Needham & Company Boosts PT on Acadia Pharmaceuticals (ACAD) by 78%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Stocks rattled, Treasuries rally after Israel attacks Iran
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Oil surges as reports of Israeli strike on Iran roil markets
- Reports of Israeli attack on Iran spark rush to yen, Swiss franc
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Acadia Pharmaceuticals (ACAD) Sees Profit-Taking after Major Run-Up
April 12, 2013 9:58 AM EDTAfter surging 64 percent Thursday on news the company plans to file pimavanserin in Parkinson's disease psychosis in late 2014 without conducting the confirmatory 021 pivotal trial, shares of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) are seeing profit taking today.
Shares were down 7% at last check, but off the lows.... More
Jefferies Raises Acadia Pharmaceuticals (ACAD) PT to $18 on Pimavanserin Win
April 12, 2013 7:11 AM EDTJefferies boosted its price target on Acadia Pharmaceuticals (NASDAQ: ACAD) from $13 to $18 after the company announced Thursday that it intends to file for pimavanserin in Parkinsons disease psychosis in late 2014 without conducting the confirmatory 021 pivotal trial.
"We believe this is a major... More
Piper Jaffray Upgrades Acadia Pharmaceuticals (ACAD) to Overweight
April 11, 2013 11:31 AM EDTPiper Jaffray upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Neutral to Overweight with a price target of $19.00 (from $5.00).
For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on... More
Acadia Pharmaceuticals (ACAD) Surges as FDA Says Data Supports NDA Filing
April 11, 2013 7:21 AM EDTAcadia Pharmaceuticals, Inc. (NASDAQ: ACAD) is surging in pre-open action after the company announced that the FDA has agreed that the data from the pivotal Phase III -020 study, together with supportive data from other studies with pimavanserin, are sufficient to support the filing of a New Drug Application (NDA) for the treatment of Parkinsons disease psychosis (PDP).
As a result, ACADIA... More
